Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...
Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive ...
Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions.
MONECO Advisors LLC significantly increased its holdings in Bristol-Myers Squibb during the fourth quarter, nearly doubling ...
Just take a look at the healthcare sector. By all accounts, healthcare stocks should be in the dumps. The sector sold off ...
William Blair analysts have lowered their FY2027 earnings per share estimate for Bristol-Myers Squibb from $7.70 to $6.50.
This was the stock's fifth consecutive day of gains.
Looking for undervalued stocks? We identified the top undervalued stocks in March 2025. Check out the list here.
The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.
Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...